These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32766890)

  • 21. Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study.
    Moore DJ; Jain S; Dubé MP; Daar ES; Sun X; Young J; Corado K; Ellorin E; Milam J; Collins D; Blumenthal J; Best BM; Anderson P; Haubrich R; Morris SR
    Clin Infect Dis; 2018 May; 66(10):1566-1572. PubMed ID: 29228144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial.
    Aizire J; Brooks KM; Mirochnick M; Flynn PM; Butler K; Kiser JJ; Siberry GK; Fenton T; Cababasay M; Fowler MG;
    J Acquir Immune Defic Syndr; 2020 Feb; 83(2):173-180. PubMed ID: 31929405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis.
    Havens PL; Tamhane A; Stephensen CB; Schuster GU; Gordon CM; Liu N; Wilson CM; Hosek SG; Anderson PL; Kapogiannis BG; Mulligan K
    AIDS Res Hum Retroviruses; 2019 Feb; 35(2):123-128. PubMed ID: 30280906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. "I wish to remain HIV negative": Pre-exposure prophylaxis adherence and persistence in transgender women and men who have sex with men in coastal Kenya.
    Kimani M; van der Elst EM; Chirro O; Wahome E; Ibrahim F; Mukuria N; de Wit TFR; Graham SM; Operario D; Sanders EJ
    PLoS One; 2021; 16(1):e0244226. PubMed ID: 33465090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adherence to event-driven HIV PrEP among men who have sex with men in Amsterdam, the Netherlands: analysis based on online diary data, 3-monthly questionnaires and intracellular TFV-DP.
    Jongen VW; Hoornenborg E; van den Elshout MA; Boyd A; Zimmermann HM; Coyer L; Davidovich U; Anderson PL; de Vries HJ; Prins M; Schim van der Loeff MF;
    J Int AIDS Soc; 2021 May; 24(5):e25708. PubMed ID: 33973373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adherence and HIV Protection Thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among Cisgender Women: A Systematic Review.
    Wu L; Niu X; Brunelli MK; Mugwanya KK
    Curr HIV/AIDS Rep; 2024 Oct; 21(5):264-281. PubMed ID: 39120667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa.
    Stranix-Chibanda L; Anderson PL; Kacanek D; Hosek S; Huang S; Nematadzira TG; Taulo F; Korutaro V; Nakabiito C; Masenya M; Lypen K; Brown E; Ibrahim ME; Yager J; Wiesner L; Johnston B; Amico KR; Rooney JF; Chakhtoura N; Spiegel HML; Chi BH;
    Clin Infect Dis; 2021 Oct; 73(7):e1893-e1900. PubMed ID: 33341883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis.
    Ibrahim ME; Castillo-Mancilla JR; Yager J; Brooks KM; Bushman L; Saba L; Kiser JJ; MaWhinney S; Anderson PL
    AIDS Res Hum Retroviruses; 2021 Jun; 37(6):421-428. PubMed ID: 33191774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determinants of adherence to daily PrEP measured as intracellular tenofovir diphosphate concentrations over 24 months of follow-up among men who have sex with men.
    van den Elshout MA; Hoornenborg E; Coyer L; Anderson PL; Davidovich U; de Vries HJ; Prins M; Schim van der Loeff MF;
    Sex Transm Infect; 2023 Aug; 99(5):303-310. PubMed ID: 37258273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort study.
    Tapsoba JD; Cover J; Obong'o C; Brady M; Cressey TR; Mori K; Okomo G; Kariithi E; Obanda R; Oluoch-Madiang D; Chen YQ; Drain P; Duerr A
    PLoS Med; 2022 Sep; 19(9):e1004097. PubMed ID: 36095005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER Trial.
    Cespedes MS; Das M; Yager J; Prins M; Krznaric I; de Jong J; Xiao D; Shao Y; Wong P; Kintu A; Carter C; Hoornenborg E; Ruane P; Phoenix J; Younis I; Halperin J
    Transgend Health; 2024 Feb; 9(1):46-52. PubMed ID: 38312459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
    Castillo-Mancilla JR; Zheng JH; Rower JE; Meditz A; Gardner EM; Predhomme J; Fernandez C; Langness J; Kiser JJ; Bushman LR; Anderson PL
    AIDS Res Hum Retroviruses; 2013 Feb; 29(2):384-90. PubMed ID: 22935078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men.
    Seifert SM; Glidden DV; Meditz AL; Castillo-Mancilla JR; Gardner EM; Predhomme JA; Rower C; Klein B; Kerr BJ; Guida LA; Zheng JH; Bushman LR; Anderson PL
    Clin Infect Dis; 2015 Mar; 60(5):804-10. PubMed ID: 25409469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate.
    Yager JL; Brooks KM; Castillo-Mancilla JR; Nemkov C; Morrow M; Peterson S; Ibrahim M; Bushman L; Kiser JJ; MaWhinney S; Anderson PL
    AIDS; 2021 Dec; 35(15):2481-2487. PubMed ID: 34482350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
    Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ;
    Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial.
    Herrera C; Serwanga J; Else L; Limakatso L; Opoka D; Ssemata AS; Pillay AD; Namubiru P; Seiphetlo TB; Odoch G; Mugaba S; Seatlholo P; Alieu A; Penchala SD; Muhumuza R; Alinde B; Petkov S; O'Hagan K; Callebaut C; Seeley J; Weiss H; Khoo S; Chiodi F; Gray CM; Kaleebu P; Webb EL; Martinson N; Fox J;
    EBioMedicine; 2023 Jul; 93():104648. PubMed ID: 37327677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis.
    Pyra M; Anderson PL; Hendrix CW; Heffron R; Mugwanya K; Haberer JE; Thomas KK; Celum C; Donnell D; Marzinke MA; Bukusi EA; Mugo NR; Asiimwe S; Katabira E; Baeten JM;
    AIDS; 2018 Aug; 32(13):1891-1898. PubMed ID: 29894385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring.
    Gandhi M; Glidden DV; Liu A; Anderson PL; Horng H; Defechereux P; Guanira JV; Grinsztejn B; Chariyalertsak S; Bekker LG; Grant RM;
    J Infect Dis; 2015 Nov; 212(9):1402-6. PubMed ID: 25895984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concordance between daily diary reported pre-exposure prophylaxis intake and intraerythrocytic tenofovir diphosphate in the Amsterdam Pre-exposure Prophylaxis demonstration project.
    Wijstma ES; Jongen VW; Boyd A; van den Elshout MAM; de Vries HJC; Davidovich U; Anderson PL; Prins M; Hoornenborg E; Schim van der Loeff MF
    AIDS; 2024 Jul; 38(8):1248-1256. PubMed ID: 38518076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections.
    Castillo-Mancilla JR; Morrow M; Coyle RP; Coleman SS; Gardner EM; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Mawhinney S; Anderson PL
    Clin Infect Dis; 2019 Apr; 68(8):1335-1342. PubMed ID: 30137238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.